Trinity Biotech to enter cardiac diagnostics with novel guideline-compliant point-of-care system
High-sensitivity ACC, ESC and AHA guideline-compliant Troponin assay offers true point-of-care capability
Trinity Biotech is showcasing its new Meritas Troponin I (TnI) point-of-care test (POC) at this week’s MEDICA trade fair in Düsseldorf, Germany.
This landmark Troponin I test is the only high-sensitivity, ACC, ESC and AHA guideline-compliant Troponin assay offering true point-of-care capability.
Designed for use with the Meritas POC Analyzer, the Meritas Troponin I test enables fast, accurate triage and intervention for patients presenting at the emergency department with a possible myocardial infarction (MI), as well as for risk stratification of patients.
Results, which are traceable to NIST SRM 2921, are comparable to those obtained using traditional top-performing laboratory analysers, and are available in just 15 minutes.
Turnaround times, patient care and outcomes are improved, helping to maximise resources and generate significant cost savings.
Studies are currently underway to validate the clinical performance of the Meritas Troponin I POC test to obtain CE marking, and additional assays are being developed to extend the test menu further.